Is It Time to Ditch Your Eli Lilly Stock?
Eli Lilly leads the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. Eli Lilly’s valuation looks stretched right now — relative to both the industry and the overall market. 10 Stocks We Like More Than Eli Lilly … Read more